TG Therapeutics is expected to report Q3 2026 revenue of $245.47 million and EPS of $0.37, while the stock currently trades at $61.18 against an average analyst price target of $69.71.
The primary focus for investors is the commercial execution and sales momentum of BRIUMVI, the company's flagship multiple sclerosis treatment. Market participants are looking for evidence that strong top-line growth can finally translate into consistent profitability following a string of recent earnings misses.
Concerns remain regarding elevated R&D and manufacturing expenses, which have pressured margins despite robust double-digit revenue expansion.